321 related articles for article (PubMed ID: 29915428)
1. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
Alvarez MJ; Subramaniam PS; Tang LH; Grunn A; Aburi M; Rieckhof G; Komissarova EV; Hagan EA; Bodei L; Clemons PA; Dela Cruz FS; Dhall D; Diolaiti D; Fraker DA; Ghavami A; Kaemmerer D; Karan C; Kidd M; Kim KM; Kim HC; Kunju LP; Langel Ü; Li Z; Lee J; Li H; LiVolsi V; Pfragner R; Rainey AR; Realubit RB; Remotti H; Regberg J; Roses R; Rustgi A; Sepulveda AR; Serra S; Shi C; Yuan X; Barberis M; Bergamaschi R; Chinnaiyan AM; Detre T; Ezzat S; Frilling A; Hommann M; Jaeger D; Kim MK; Knudsen BS; Kung AL; Leahy E; Metz DC; Milsom JW; Park YS; Reidy-Lagunes D; Schreiber S; Washington K; Wiedenmann B; Modlin I; Califano A
Nat Genet; 2018 Jul; 50(7):979-989. PubMed ID: 29915428
[TBL] [Abstract][Full Text] [Related]
2. Expression and Molecular Regulation of the Cox2 Gene in Gastroenteropancreatic Neuroendocrine Tumors and Antiproliferation of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs).
Gao F; Zafar MI; Jüttner S; Höcker M; Wiedenmann B
Med Sci Monit; 2018 Nov; 24():8125-8140. PubMed ID: 30420588
[TBL] [Abstract][Full Text] [Related]
3. Clinical application of microRNA testing in neuroendocrine tumors of the gastrointestinal tract.
Vicentini C; Fassan M; D'Angelo E; Corbo V; Silvestris N; Nuovo GJ; Scarpa A
Molecules; 2014 Feb; 19(2):2458-68. PubMed ID: 24566314
[TBL] [Abstract][Full Text] [Related]
4. Identification of the BRAF V600E mutation in gastroenteropancreatic neuroendocrine tumors.
Park C; Ha SY; Kim ST; Kim HC; Heo JS; Park YS; Lauwers G; Lee J; Kim KM
Oncotarget; 2016 Jan; 7(4):4024-35. PubMed ID: 26684240
[TBL] [Abstract][Full Text] [Related]
5. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
6. BRAF
Dizdar L; Werner TA; Drusenheimer JC; Möhlendick B; Raba K; Boeck I; Anlauf M; Schott M; Göring W; Esposito I; Stoecklein NH; Knoefel WT; Krieg A
Int J Cancer; 2019 Mar; 144(6):1379-1390. PubMed ID: 30144031
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium.
Iyer R; Phan AT; Boudreaux JP
Clin Adv Hematol Oncol; 2017 Apr; 15 Suppl 4(4):1-24. PubMed ID: 28654022
[TBL] [Abstract][Full Text] [Related]
8. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines.
Hofving T; Arvidsson Y; Almobarak B; Inge L; Pfragner R; Persson M; Stenman G; Kristiansson E; Johanson V; Nilsson O
Endocr Relat Cancer; 2018 Mar; 25(3):367-380. PubMed ID: 29444910
[TBL] [Abstract][Full Text] [Related]
9. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
[TBL] [Abstract][Full Text] [Related]
10. Signaling networks and the feasibility of computational analysis in gastroenteropancreatic neuroendocrine tumors.
Chen P; Wang Q; Xie J; Kwok HF
Semin Cancer Biol; 2019 Oct; 58():80-89. PubMed ID: 31054326
[TBL] [Abstract][Full Text] [Related]
11. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
Strosberg JR
Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
[TBL] [Abstract][Full Text] [Related]
12. Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.
Hoffman SE; Dowrey TW; Villacorta Martin C; Bi K; Titchen B; Johri S; DelloStritto L; Patel M; Mackichan C; Inga S; Chen J; Grimaldi G; Napolitano S; Wakiro I; Wu J; Yeung J; Rotem A; Sicinska E; Shannon E; Clancy T; Wang J; Denning S; Brais L; Besson NR; Pfaff KL; Huang Y; Kao KZ; Rodig S; Hornick JL; Vigneau S; Park J; Kulke MH; Chan J; Van Allen EM; Murphy GJ
Sci Adv; 2023 Sep; 9(39):eadd9668. PubMed ID: 37756410
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
14. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
15. Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma.
Dijkstra KK; van den Berg JG; Weeber F; van de Haar J; Velds A; Kaing S; Peters DDGC; Eskens FALM; de Groot DA; Tesselaar MET; Voest EE
Front Endocrinol (Lausanne); 2021; 12():627819. PubMed ID: 33776923
[TBL] [Abstract][Full Text] [Related]
16. c-MET inhibition: novel treatment for sporadic and MEN1-associated GEP NETs.
Lee ME; Tepede AA; Mandl A; Weinstein LS; Del Rivero J; Agarwal SK; Blau JE
J Mol Endocrinol; 2020 Aug; 65(2):R1-R17. PubMed ID: 32384260
[TBL] [Abstract][Full Text] [Related]
17. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
[TBL] [Abstract][Full Text] [Related]
18. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors.
Carmona-Bayonas A; Jiménez-Fonseca P; Custodio A; Grande E; Capdevila J; López C; Teule A; Garcia-Carbonero R;
Curr Oncol Rep; 2017 Sep; 19(11):72. PubMed ID: 28920153
[TBL] [Abstract][Full Text] [Related]
20. Expression profiling of small intestinal neuroendocrine tumors identifies subgroups with clinical relevance, prognostic markers and therapeutic targets.
Andersson E; Arvidsson Y; Swärd C; Hofving T; Wängberg B; Kristiansson E; Nilsson O
Mod Pathol; 2016 Jun; 29(6):616-29. PubMed ID: 26965582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
